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of TCRab chains, in both mice and
humans, approximately one-third of pe-
ripheral T cells are dual-TCR T cells, al-
though the number of cells with the cell
surface expression is low (Padovan
et al., 1993). If these dual-TCR T cells con-
tain anergic T cells against the self-anti-
gens, then activation of these cells via
the second TCR by environmental anti-
gens such as viruses may cause autoim-
mune diseases. However, it is intriguing
to notice that in the tolerant TCRGag P14
double TCR Tg mice, the LCMV infection
failed to induce any detectable autoim-
mune damage in the liver, which ex-
pressed Gag antigen. Thus, in the future,
understanding of the mechanisms that
caused such a discrepancy may help to
stimulate wanted immune response and
prevent unwanted autoimmune conse-
quences in clinical therapy.
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Although interferon-b is the most popular treatment for multiple sclerois, its mechanism of action remains
enigmatic. In this issue of Immunity, Prinz et al. (2008) elucidate an intriguing portrait of the pleiotropic effects
of type 1 interferons in taming brain inflammation.Type 1 interferons (IFNs) are a family of
cytokines consisting of IFN-b andmultiple
subtypes of IFN-a. Originally, these cyto-
kines were identified by their antiviral
properties, but now they are known to
possess anti-inflammatory effects. Type
1 interferons inhibit several components
of the immune system, and currently,
IFN-b is the clinician’s most popular
choice for initial treatment of relapsing re-
mitting multiple sclerosis (MS). In general,
IFN-b reduces relapses by approximately
one-third of the cases and somewhat
delays progression of disease. However,
it works in only 50% of patients with
MS, and its toxicities are frequent (Arna-
son, 1999). Despite its wide use, the
precise mechanism by which IFN-b -
suppresses CNS autoimmunity in MS is
still unclear. In a series of elegant experi-
ments described in this issue, Prinz et al.600 Immunity 28, May 2008 ª2008 Elsevier(2008) demonstrated that local produc-
tion of IFN-b in the central nervous sys-
tem (CNS) suppresses experimental
autoimmune encephalomyelitis (EAE) by
inhibiting expression of certain chemo-
kines and bymodulating antigen process-
ing and presentation in microglia and
macrophages.
Pinpointing the precise mechanism by
which IFN-b attenuates CNS autoimmu-
nity is not an easy task. First, MS and its
model disease, EAE, are highly complex
pathological processes that involve sev-
eral different cell types, with some initiat-
ing disease and with others participating
in the progression of paralysis. Obtaining
MS tissue at various disease stages in it-
self is a difficult feat, because brain tissue
is not ordinarily biopsied. Proteomic stud-
ies have been performed however on dif-
ferent stages of disease in MS and revealInc.a considerable signature of interferon-
inducible proteins (Han et al., 2008). Cell
types targeted by IFN-b include, but are
not limited, to dendritic cells (DCs), T
cells, B cells, macrophages, neutrophils,
microglia, astrocytes, and neurons. Sec-
ond, the effects of IFN-b are not limited
to only one of these specific cell types.
Type 1 IFN receptors (IFNARs) are ex-
pressed on a wide variety of cells and tis-
sues. Furthermore, IFN-b has been shown
to inhibit several inflammatory processes
of the immune system, including downre-
gulation of the expression of MHC class II
molecules on DCs, suppression of pro-
inflammatory cytokine production, reduc-
tion of proliferation of T cells, limitation
of immune cell trafficking, and promotion
of the integrity of endothelial cell barrier
between the blood and the CNS (Benve-
niste and Qin, 2007).
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IFN-b is expressed at markedly higher
amounts in the CNS than in the periphery
during the acute and chronic phases of
EAE. This alone is an intriguing observa-
tion in light of a previous study that
assessed the progression of EAE in IFN-
b-deficient mice (Teige et al., 2003). IFN-
b-deficient mice exhibited exacerbated
EAE after induction with myelin basic pro-
tein. However, the IFN-b deficiency does
not alter the proliferative capacity or cyto-
kine production from lymph node cells
after the immunization with myelin basic
protein. This observation suggests that
endogenously expressed IFN-b does not
affect immune cell function in the periph-
ery during EAE. At the time, this was
a striking and somewhat paradoxical find-
ing because it had been established that
IFN-b directly inhibits both dendritic cells
and T cell function, but now this observa-
tion can be explained by the fact that
IFN-b is increased in the CNS but not in
the periphery during EAE.
This increase in expression of IFN-b in
theCNSbegs forananswer to thequestion:
What is being inhibited by local IFN-b sig-
naling in CNS autoimmunity? In order to
answer this,Prinzetal. (2008) analyzedEAE
in mice deficient for IFNAR. They assessed
T cells, B cells, neuroectodermal cells and
myeloid cells in a variety of tissues.
Mice with complete deletion of IFNAR
had worse degrees of clinical paralysis
during the acute and chronic phases of
EAE. This increase in disease was associ-
ated with elevated numbers of infiltrating
macrophages and activated microglia in
the CNS. This correlated with amplified
expression of the chemokines CCL2
(also known as MCP1), CCL5 (RANTES),
and CCL10 (MIP-1g), which are all strong
chemoattractants for myeloid cells.
It is remarkable that the lack of IFNAR
had no effect on CD4+ T cells, which in-
vade the brain and spinal cord in EAE.
First, T cells express receptors to RANTES
and CCL2, and these chemokines influ-
ence CD4+ T cell differentiation and traf-
ficking to inflamed tissue. Second, effector
T cells are a major source of chemokines.
Third, IFN-b can directly inhibit T cell
proliferation and alter function of effector
T helper cells. Therefore, the presence of
IFN-b in the CNS could have a major
effect on CD4+ T cells, which could
markedly suppress EAE. However, Prinz
et al. (2008) find that mice with IFNARFigure 1. Role of Type 1 Interferons in Brain Inflammmation
Locally expressed IFN-b in theCNSsuppresseschemokine secretion, decreasesantigenpresentation, and
increases IL-27 production from microglia, infiltrating macrophages and DCs. These effects attenuate
inflammationbyaltering theeffector functionand traffickingof infiltratingCD4+Tcells andother immunecells.deleted specifically in T cells have a slight
increase in the onset of symptoms, al-
though they eventually develop clinical
scores that are similar to control mice.
Even though this finding is surprising,
it actually supports existing literature.
IFN-b alters naive CD4+ T cell function,
but upon antigen stimulation, activated
CD4+ T cells lose sensitivity to IFN-b
stimulation (Dondi et al., 2003). In the
model of EAE used by Prinz et al. (2008),
in which most myelin-specific CD4+ T
cell are activated in the secondary lym-
phoid tissues, the local production IFN-
b in the CNS may not have a great effect
on the infiltrating CD4+ T cell.
B cells have anti-inflammatory effects in
EAE. This could be explained by the ob-
servation that IFN-b signaling upregulates
IL-10 in B cells, resulting in marked anti-
inflammatory effects (Zhang et al., 2007).
Therefore, it is possible that B cells could
be targeted by IFN-b and would contrib-
ute to the inhibition of EAE symptoms.
However, specific deletion of IFNAR in B
cells had no effect on the progression of
EAE. This is surprising because B cells
are detectable in the CNS during acute
and chronic EAE, and thus the local pro-
duction of IFN-b in the CNS might have
affected B cells, but instead it did not.
Astrocytes and other CNS-specific cells
are potential sources of chemokines that
recruit inflammatory cells to the CNS dur-
ing EAE. However, the specific deletion of
IFNAR in neuroectodermal cells, which in-
clude neurons, astrocytes, and oligoden-Immdrocytes, had no effect on the progression
of acute and chronic EAE, suggesting that
type1 IFNsignalingdoesnotaffect expres-
sion of chemokines from these cells during
EAE. This may indeed be true because it
has been shown that after inflammatory
stimulus, astrocytes actually coexpress
IFN-b and CCL5 (Rivieccio et al., 2005).
Specific deletion of type 1 IFN signaling
in myeloid cells exacerbated EAE symp-
toms substantially in the chronic phase
of the disease. DCs, macrophages, and
microglia are integral to the induction
and effector phases of EAE, including
antigen processing and presentation,
chemokine expression, and injury to
axons. All these functions can be inhibited
by IFN-b signaling. Prinz et al. (2008)
demonstrate that local IFN-b signaling
suppresses three important functions of
macrophages and microglia: chemokine
expression, phagocytosis of myelin anti-
gen, and upregulation of MHC class II.
This article sheds light on the role en-
dogenously expressed IFN-b has in CNS
autoimmunity. The data support the fol-
lowing model (Figure 1). During inflamma-
tion of the CNS, IFN-b and other type 1
IFNs are locally elevated at the site of in-
flammation. This is yet another example
of the endogenous protective mecha-
nisms that are elicited upon inflammation
of the brain, an organ that cannot tolerate
inflammation well. A panoply of guardians
are induced to protect the brain when it is
under attack, including aB crystallin and,
as we recognize now, IFN-b (Ousmanunity 28, May 2008 ª2008 Elsevier Inc. 601
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Previewset al., 2007). IFN-b signaling, in turn, sup-
presses chemokine secretion by micro-
glia, and this suppression decreases in-
filtration by peripheral immune cells. In
addition, IFN-b decreases the uptake
and presentation of other nervous tissue
antigens and inhibits the amplification of
inflammation via epitope spreading.
Recently, in another publication, Guo
et al. also examined the role of type 1
IFN signaling in EAE (Guo et al., 2008).
They too discovered that IFNAR-deficient
mice had defects in innate immune cell
function, but they report a striking differ-
ence between those reported by Prinz
et al. (2008) on the effects of type 1 IFN
on the development of T helper 17
(Th17) cells. Prinz et al. (2008) observed
no effect on the development of Th17
cells or expression of cytokines involved
in their function. In contrast, Guo et al.
(2008) demonstrated that the immuno-
suppressive effect of type 1 IFN is due to
the downregulation of IL-23 and upregula-
tion of IL-27, which is now known to inhibit
Th17 cell differentiation. What could be
the reason for these conflicting data?
On close inspection of the methods,
there is a considerable difference in how
each group induced disease. Prinz et al.
(2008) used much less mycobacterium in
the adjuvant than Guo (1 ug/ml versusTaking a Toll Road
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Effective subunit vaccines must elici
(2008) find that the ability of adjuva
receptor engagement.
Charlie Janeway referred to adjuvants as
‘‘the immunologist’s dirty little secret,’’
but they still offer the best hope for estab-
lishing safer and more effective subunit
vaccines (Janeway, 1989). Adjuvants are
nonspecific stimulators of the immune
602 Immunity 28, May 2008 ª2008 Elsevier I8 mg/ml). This difference could have a
profound influence on the activation and
cytokine production of the innate immune
system and could be the cause of this
important discordance in experimental
outcomes.
IFN-bhasbeenanexceptionally popular
therapy for relapsing remitting MS. Be-
cause we now understand that IFN-b is
a natural protector of brain tissue from in-
flammation, it is clear why exogenous ad-
ministration of this cytokine has beneficial
effects in diseases such as MS. However,
not all patients respond to treatment.
Therefore, defining the mechanisms re-
sponsible for the therapeutic effects of
IFN-b has high relevance. Future studies,
using both human and mouse models,
mustbedesigned toaddresswhatactually
happens when IFN-b is administered as
a therapy. Even though Prinz et al. (2008)
do not elucidate the therapeutic mecha-
nism of IFN-b, they describe an intriguing
mechanismbywhichnatural type1 IFNex-
pressed in the mouse suppresses inflam-
mationandautoimmunity in theCNS.Prinz
et al. (2008) have made an important dis-
covery that provides key information for
the community of scientists and physi-
cians interested in demyelinating diseases
such as MS and also for immunologists
interested in autoimmunity in general.to Better Vaccine
llen1,*
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t strong CD4+ T cell responses. In thi
nts to stimulate high-avidity T cell r
system, and many are thought to operate
through activation of Toll-like receptors
on antigen-presenting cells (McKee et al.,
2007). However, the molecular mecha-
nisms underlying adjuvant effects have
not beenwell defined. Todesign adjuvants
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esponses correlates with Toll-like-
best suited to improvevaccine immunoge-
nicity without increasing unwanted side
effects, wemust first delineate the proper-
ties that define good adjuvants and then
elucidate theirmolecular effects. Theeffect
of adjuvants on T cell responses has, until
